Results of malignancy detection during prophylactic medical examinations in 2013—2014

Александрова, Л. М.; Starinsky, V. V.; Калинина, А. М.; Каприн, А. Д.; Boytsov, S. А.

doi:10.17116/terarkh201688160-66

Cited by 5 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor is symptomless at the early stages. According to an analysis of the main parameters of oncological healthcare in Russia in 2021, PCa was detected at stage IV in 59.5% of patients [ 2 ]. Survival rates remain dramatically low: first-year mortality in patients with metastatic PCa is 67.3%, and 5-year survival rate is 3% [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…According to an analysis of the main parameters of oncological healthcare in Russia in 2021, PCa was detected at stage IV in 59.5% of patients [ 2 ]. Survival rates remain dramatically low: first-year mortality in patients with metastatic PCa is 67.3%, and 5-year survival rate is 3% [ 2 , 3 ]. While chemotherapy is the main treatment strategy for metastatic PCa, all the common regimes failed to improve the progression-free survival rate significantly [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis

Shatalov,

Falaleeva,

Bykova

et al. 2024

Oncotarget

View full text Add to dashboard Cite

About 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known for its lowest survival rates among all oncological diseases and heterogenic molecular profile. Enormous amount of genetic changes, including somatic mutations, exceeds the limits of routine clinical genetic laboratory tests and further stagnates the development of personalized treatments. We aimed to build a mutational landscape of PCa in the Russian population based on full exome next-generation sequencing (NGS) of the limited group of patients. Applying a machine learning model on full exome individual data we received personalized recommendations for targeted treatment options for each clinical case and summarized them in the unique therapeutic landscape.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis

Shatalov,

Falaleeva,

Bykova

et al. 2024

Oncotarget

View full text Add to dashboard Cite

show abstract

Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer

Новикова

Nosov²,

Panov

et al. 2021

Gynecologic Oncology

View full text Add to dashboard Cite

Trends in Morbidity and Hospital Lethality from Neoplasms before and during the New Coronavirus Infection COVID-19

et al. 2021

View full text Add to dashboard Cite

Background. Taking into account the special medical and social significance of oncological diseases, as well as taking into account that patients suffering from neoplasms are a special risk group for developing complications of coronavirus infection, it seems relevant to study the impact of the COVID-19 pandemic on the level of morbidity and hospital lethality of patients with neoplasms. Aims to study the trends of morbidity and hospital lethality due to neoplasms in the Russian Federation before and during the pandemic of the new coronavirus infection COVID-19. Methods. The indicators of primary and general morbidity, hospital lethality from neoplasms of the adult population were calculated on the basis of federal statistical observation data contained in reporting forms No. 12 and No. 14 of all subjects of the Russian Federation for 20152020. Results. During the period from 2015 to 2019, an increase in the general (by 14.8%) and primary (by 4.8%) incidence of neoplasms was noted in the Russian Federation. In 2020, compared with 2019, on the contrary, the indicators of general (by 5.0%) and primary (by 17.4%) incidence of neoplasms decreased. Hospital lethality due to neoplasms also increased during 20152019, in total it increased by 19.2%, in one year (2020) hospital lethality increased by 6.6%. A similar situation has developed in all federal districts and most regions of the country. Conclusions. The decline in the incidence of neoplasms in 2020, with their previous continuous growth, reflects the difficult situation that has developed during the pandemic of a new coronavirus infection in the healthcare of the Russian Federation. The increase in hospital lethality from neoplasms indicates a more severe course of coronavirus infection in adult patients with malignant neoplasms and a more frequent development of fatal complications in them.

show abstract

Results of malignancy detection during prophylactic medical examinations in 2013—2014

Cited by 5 publications

References 3 publications

Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis

Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis

Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer

Trends in Morbidity and Hospital Lethality from Neoplasms before and during the New Coronavirus Infection COVID-19

Contact Info

Product

Resources

About